EG24957A - Quinazoline derivatives as src tyrosine kinase inhibitors. - Google Patents

Quinazoline derivatives as src tyrosine kinase inhibitors.

Info

Publication number: EG24957A
Authority: EG; Egypt
Prior art keywords: tyrosine kinase; kinase inhibitors; quinazoline derivatives; src tyrosine; src
Prior art date: 2002-11-04

Application number

Other languages

English (en)

Inventor

Patrick Ple

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-04

Filing date

2005-04-30

Publication date

2011-02-28

2005-04-30 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-02-28 Application granted granted Critical

2011-02-28 Publication of EG24957A publication Critical patent/EG24957A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EGNA2005000178 2002-11-04 2005-04-30 Quinazoline derivatives as src tyrosine kinase inhibitors. EG24957A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02292736		2002-11-04
EP03290900		2003-04-10
PCT/GB2003/004703 WO2004041829A1 (en)	2002-11-04	2003-10-29	Quinazoline derivatives as src tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
EG24957A true EG24957A (en)	2011-02-28

Family

ID=32313852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EGNA2005000178 EG24957A (en)	2002-11-04	2005-04-30	Quinazoline derivatives as src tyrosine kinase inhibitors.

Country Status (27)

Country	Link
US (1)	US7462623B2 (pl)
EP (1)	EP1562955B1 (pl)
JP (2)	JP4593464B2 (pl)
KR (1)	KR101089462B1 (pl)
AR (1)	AR041884A1 (pl)
AT (1)	ATE387451T1 (pl)
AU (1)	AU2003278383B2 (pl)
BR (1)	BR0315756A (pl)
CA (1)	CA2503371C (pl)
CO (1)	CO5560578A2 (pl)
CY (1)	CY1108061T1 (pl)
DE (1)	DE60319410T2 (pl)
DK (1)	DK1562955T3 (pl)
EG (1)	EG24957A (pl)
ES (1)	ES2300619T3 (pl)
IL (1)	IL168013A (pl)
IS (1)	IS2568B (pl)
MX (1)	MXPA05004858A (pl)
MY (1)	MY137835A (pl)
NO (1)	NO331951B1 (pl)
NZ (1)	NZ539408A (pl)
PL (1)	PL215161B1 (pl)
PT (1)	PT1562955E (pl)
RU (1)	RU2350618C2 (pl)
SI (1)	SI1562955T1 (pl)
TW (1)	TWI320786B (pl)
WO (1)	WO2004041829A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2280003B1 (en)	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Process for preparing receptor-type kinase modulators
PT2213661E (pt)	2003-09-26	2011-12-15	Exelixis Inc	Moduladores de c-met e métodos de uso
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0427697D0 (en) *	2004-12-17	2005-01-19	Astrazeneca Ab	Chemical process
ES2364495T3 (es) *	2005-02-03	2011-09-05	The General Hospital Corporation	Método para tratar cáncer resistente a gefitinib.
WO2009068906A2 (en) *	2007-11-26	2009-06-04	Astrazeneca Ab	Combinations comprising zd4054 and a src family kinase inhibitor 172
SG173014A1 (en)	2009-01-16	2011-08-29	Exelixis Inc	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2812750C (en)	2010-09-27	2020-10-06	Exelixis, Inc.	Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
TWI577671B (zh) *	2011-11-14	2017-04-11	Sunshine Lake Pharma Co Ltd	Aminoquinazoline derivatives and salts thereof and methods of use thereof
KR20180086187A (ko)	2015-10-05	2018-07-30	더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕	자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
RS66727B1 (sr)	2018-09-10	2025-05-30	Mirati Therapeutics Inc	Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
CN119504612B (zh) *	2024-11-18	2026-04-07	中国海洋大学	一种喹唑啉茋类衍生物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5409930A (en) *	1991-05-10	1995-04-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9205320D0 (en) *	1992-03-11	1992-04-22	Ici Plc	Anti-tumour compounds
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US6046206A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
BR9707495A (pt) *	1996-02-13	1999-07-27	Zeneca Ltd	Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
US6291455B1 (en)	1996-03-05	2001-09-18	Zeneca Limited	4-anilinoquinazoline derivatives
EP0888310B1 (en) *	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
ID19609A (id)	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
KR100567649B1 (ko)	1996-09-25	2006-04-05	아스트라제네카 유케이 리미티드	혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
WO1999010349A1 (en)	1997-08-22	1999-03-04	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
BR9914167B1 (pt)	1998-09-29	2011-03-09		compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
KR100860295B1 (ko) *	1998-10-08	2008-09-25	아스트라제네카 아베	퀴나졸린 유도체
SK288365B6 (sk) *	1999-02-10	2016-07-01	Astrazeneca Ab	Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
KR20020032608A (ko)	1999-09-21	2002-05-03	다비드 에 질레스	퀴나졸린 화합물 및 이를 함유하는 제약 조성물
CZ301689B6 (cs)	1999-11-05	2010-05-26	Astrazeneca Ab	Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
ES2267748T3 (es) *	2000-04-07	2007-03-16	Astrazeneca Ab	Compuestos de quinazolina.
UA73993C2 (uk) *	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
ES2317923T3 (es) *	2000-08-09	2009-05-01	Astrazeneca Ab	Compuestos de cinolina.
CA2416525A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002012226A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Quinoline derivatives having vegf inhibiting activity
CA2419301C (en)	2000-08-21	2009-12-08	Astrazeneca Ab	Quinazoline derivatives
WO2002030926A1 (en)	2000-10-13	2002-04-18	Astrazeneca Ab	Quinazoline derivatives
US6849625B2 (en) *	2000-10-13	2005-02-01	Astrazeneca Ab	Quinazoline derivatives with anti-tumour activity
US20040063733A1 (en)	2000-10-25	2004-04-01	Lambert Christine Marie Paul	Quinazoline derivatives
DE60229046D1 (de)	2001-04-19	2008-11-06	Astrazeneca Ab	Chinazolin derivate
WO2002092578A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2002092577A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2002092579A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	4-anilinoquinazoline derivatives
US7501516B2 (en)	2001-07-16	2009-03-10	Astrazeneca Ab	Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
AU2002365664A1 (en)	2001-12-05	2003-06-17	Astrazeneca Ab	Quinoline derivatives as antitumour agents
JP4608215B2 (ja)	2002-02-01	2011-01-12	アストラゼネカアクチボラグ	キナゾリン化合物
GB0215823D0 (en)	2002-07-09	2002-08-14	Astrazeneca Ab	Quinazoline derivatives
WO2004004732A1 (en)	2002-07-09	2004-01-15	Astrazeneca Ab	Quinazoline derivatives for use in the treatment of cancer
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
KR20050056190A (ko)	2002-08-09	2005-06-14	아스트라제네카 아베	암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
PT1592423E (pt)	2003-02-13	2011-06-16	Astrazeneca Ab	Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent

2003
- 2003-10-29 RU RU2005117337/04A patent/RU2350618C2/ru not_active IP Right Cessation
- 2003-10-29 BR BR0315756-3A patent/BR0315756A/pt not_active IP Right Cessation
- 2003-10-29 DE DE60319410T patent/DE60319410T2/de not_active Expired - Lifetime
- 2003-10-29 CA CA2503371A patent/CA2503371C/en not_active Expired - Fee Related
- 2003-10-29 PL PL376255A patent/PL215161B1/pl unknown
- 2003-10-29 WO PCT/GB2003/004703 patent/WO2004041829A1/en not_active Ceased
- 2003-10-29 JP JP2005502127A patent/JP4593464B2/ja not_active Expired - Fee Related
- 2003-10-29 KR KR1020057007855A patent/KR101089462B1/ko not_active Expired - Fee Related
- 2003-10-29 EP EP03769689A patent/EP1562955B1/en not_active Expired - Lifetime
- 2003-10-29 NZ NZ539408A patent/NZ539408A/en not_active IP Right Cessation
- 2003-10-29 PT PT03769689T patent/PT1562955E/pt unknown
- 2003-10-29 AT AT03769689T patent/ATE387451T1/de active
- 2003-10-29 DK DK03769689T patent/DK1562955T3/da active
- 2003-10-29 SI SI200331192T patent/SI1562955T1/sl unknown
- 2003-10-29 AU AU2003278383A patent/AU2003278383B2/en not_active Ceased
- 2003-10-29 ES ES03769689T patent/ES2300619T3/es not_active Expired - Lifetime
- 2003-10-29 US US10/533,931 patent/US7462623B2/en not_active Expired - Fee Related
- 2003-10-29 MX MXPA05004858A patent/MXPA05004858A/es active IP Right Grant
- 2003-10-30 TW TW092130284A patent/TWI320786B/zh not_active IP Right Cessation
- 2003-11-03 MY MYPI20034197A patent/MY137835A/en unknown
- 2003-11-04 AR ARP030104036A patent/AR041884A1/es not_active Application Discontinuation
2005
- 2005-04-13 IL IL168013A patent/IL168013A/en not_active IP Right Cessation
- 2005-04-19 NO NO20051900A patent/NO331951B1/no not_active IP Right Cessation
- 2005-04-30 EG EGNA2005000178 patent/EG24957A/xx active
- 2005-05-03 CO CO05042313A patent/CO5560578A2/es not_active Application Discontinuation
- 2005-05-19 IS IS7849A patent/IS2568B/is unknown
2008
- 2008-04-24 CY CY20081100460T patent/CY1108061T1/el unknown
2010
- 2010-07-26 JP JP2010167576A patent/JP2010270143A/ja active Pending

Also Published As

Publication number	Publication date
IS7849A (is)	2005-05-19
AR041884A1 (es)	2005-06-01
CO5560578A2 (es)	2005-09-30
JP2006506463A (ja)	2006-02-23
ATE387451T1 (de)	2008-03-15
DE60319410T2 (de)	2009-02-19
RU2005117337A (ru)	2006-01-20
DK1562955T3 (da)	2008-06-02
TW200420567A (en)	2004-10-16
MXPA05004858A (es)	2005-07-22
MY137835A (en)	2009-03-31
RU2350618C2 (ru)	2009-03-27
TWI320786B (en)	2010-02-21
AU2003278383B2 (en)	2007-06-14
EP1562955B1 (en)	2008-02-27
JP4593464B2 (ja)	2010-12-08
NO331951B1 (no)	2012-05-14
JP2010270143A (ja)	2010-12-02
CY1108061T1 (el)	2014-02-12
KR20050074526A (ko)	2005-07-18
WO2004041829A1 (en)	2004-05-21
KR101089462B1 (ko)	2011-12-07
EP1562955A1 (en)	2005-08-17
IS2568B (is)	2010-01-15
US7462623B2 (en)	2008-12-09
PL215161B1 (pl)	2013-10-31
BR0315756A (pt)	2005-09-06
NZ539408A (en)	2007-09-28
HK1079195A1 (en)	2006-03-31
ES2300619T3 (es)	2008-06-16
CA2503371C (en)	2011-01-11
NO20051900L (no)	2005-06-01
US20060122199A1 (en)	2006-06-08
CA2503371A1 (en)	2004-05-21
IL168013A (en)	2013-03-24
PT1562955E (pt)	2008-05-05
DE60319410D1 (en)	2008-04-10
PL376255A1 (pl)	2005-12-27
AU2003278383A1 (en)	2004-06-07
SI1562955T1 (sl)	2008-06-30

Publication	Publication Date	Title
IL174261A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
IL174258A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
IL173200A0 (en)	2006-06-11	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003299651A8 (en)	2004-06-30	Tyrosine kinase inhibitors
AU2003233455A1 (en)	2003-10-13	Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
AP2005003353A0 (en)	2005-09-30	Diazepinoindole derivatives as kinase inhibitors.
AU2003298942A8 (en)	2004-06-30	Tyrosine kinase inhibitors
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
MXPA03008690A (es)	2003-12-12	Inhibidores novedosos de tirosina cinasa.
EP1581539A4 (en)	2007-09-19	NEW TYROSINE KINASE HEMMER
AU2003275282A8 (en)	2004-04-23	Novel tyrosine kinase inhibitors
EG24957A (en)	2011-02-28	Quinazoline derivatives as src tyrosine kinase inhibitors.
IL184798A0 (en)	2007-12-03	Quinazoline derivatives as tyrosine kinase inhibitors
AU2002323406A1 (en)	2003-03-18	Tyrosine kinase inhibitors
AU2002327534A1 (en)	2003-03-03	Tyrosine kinase inhibitors
AU2002253350A1 (en)	2002-11-11	4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
GB0201384D0 (en)	2002-03-13	Tyrosine kinase inhibitors
HK1090052A (en)	2006-12-15	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
HK1122563A (en)	2009-05-22	4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
HK1112903A (en)	2008-09-19	Quinazoline derivatives as tyrosine kinase inhibitors
AU2003237902A1 (en)	2003-09-02	Tyrosine kinase inhibitors
IS8386A (is)	2006-03-30	Kínasólínafleiður sem týrósínkínasatálmar
AU2002337760A1 (en)	2003-04-07	2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
AU2002337762A1 (en)	2003-04-07	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
SI1684750T1 (sl)	2010-09-30	aminoariloksazolne spojine kot inhibitorji tirozin kinaze